25.7% of the cases were negative for IMP2/p62 expression, whereas from 74.3% positive samples 86.0% showed low IMP2/p62 expression and 14.0% highly expressed IMP2/p62 (Figure 1A) without being frequently mutated: mutations in the IGF2BP2 gene were observed in 1.35% of GBC cases investigated (n = 74) and in 0% of bile duct cancer samples (n = 294) (Sanger Institute COSMIC website, http://www.sanger.ac.uk/cosmic). This evidence concerns the gene IGF2BP2 and bile duct cancer.